HALB (Halberd) Payments of Debt: $0.00 Mil (TTM As of Jul. 2023)


What is Halberd Payments of Debt?

Halberd HALB Payments of Debt is $0.00 Mil as of Jul. 2023.

Halberd's Payments of Debt for the six months ended in Jul. 2023 was $0.00 Mil.

Halberd's Payments of Debt for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Halberd Payments of Debt Related Terms

Halberd Payments of Debt Historical Data

* Premium members only.

The historical data trend for Halberd's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Payments of Debt Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Payments of Debt
0.00 0.00 0.00

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Payments of Debt 0.00 0.00 0.00

Halberd Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Payments of Debt for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Halberd (HALB) has a Payments of Debt of $0.00 Mil as of Jul. 2023. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Halberd and its competitors.
Is Halberd's Payments of Debt too high?
Halberd's current Payments of Debt is $0.00 Mil.
How does Halberd's Payments of Debt compare to GRI and OCEA?
Halberd's Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Halberd and its competitors. Halberd's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Halberd (HALB), the current Payments of Debt is $0.00 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.